OncoC4
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, OncoC4 sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
OncoC4: 7 sponsored US clinical trials, 3 recruiting.
OncoC4 sponsors 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. 1 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumor, with 3 trials.
Upper-quartile sponsor footprint
OncoC4 sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
NCT06635785
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
NCT06352359
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
NCT05671510
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
NCT05682443
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
NCT05446298
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
NCT04140526
Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors
NCT07408258
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the OncoC4 pipeline
3 recruiting of 7 indexed (43% open).
Phase mix: 1 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Advanced Solid Tumor (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
OncoC4: open-pipeline peers nationwide
Peers matched on 7 registered trials and 43% open enrollment, not the therapeutic-area sidebar.
OncoC4 sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 43% open enrollment (± trial volume)
- Alphatec Spine · 43% recruiting · 7 trials
- Clarity Pharmaceuticals · 43% recruiting · 7 trials
- Colorado Center for Reproductive Medicine · 43% recruiting · 7 trials
- David Moss · 43% recruiting · 7 trials
Related
What to do with this OncoC4 page
7 registered trials is a research-attention snapshot, not an endorsement of OncoC4 or any single study.
- 3 of OncoC4's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Solid Tumor is the condition OncoC4 studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumor trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
OncoC4 pipeline card: 7 registered trials from official public datasets.Report a data error.